Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma

Cancer medicine

Volumn 3, Issue 3, 2014, Pages 592-602

  Wong, Eric T ^a   Lok, Edwin ^a   Swanson, Kenneth D ^a   Gautam, Shiva ^a   Engelhard, Herbert H ^a   Lieberman, Frank ^a   Taillibert, Sophie ^a   Ram, Zvi ^a   Villano, John L ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

NovoTTF 100A; recurrent glioblastoma; response

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; BRAIN NEOPLASMS; DEVICES; DISEASE FREE SURVIVAL; ELECTROMAGNETIC RADIATION; GLIOBLASTOMA; HUMAN; MIDDLE AGED; MITOSIS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RADIATION RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; ELECTROMAGNETIC RADIATION; EQUIPMENT AND SUPPLIES; GLIOBLASTOMA; HUMANS; MIDDLE AGED; MITOSIS; NEOPLASM RECURRENCE, LOCAL;

EID: 84900466461     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.210     Document Type: Article

References (0)